Bartee, Amy
Eli Lilly (United States)
3 papers on CoChatORCID 0009-0005-1355-8331
Most cited papers
- Verified
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 248
- Verified
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj, H. S., Welch, M., Shah, P., Luna, E., Jaouimaa, F.-Z., Liu, B., Liu, R., Chen, Y., Patel, H., & Bartee, A. (2026) · The Lancet
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 23
- Verified
Predictive Low-Glucose Suspend Necessitates Less Carbohydrate Supplementation to Rescue Hypoglycemia: Need to Revisit Current Hypoglycemia Treatment Guidelines
Pinsker, J. E., Bartee, A., Katz, M., Lalonde, A., Jones, R., Dassau, E., & Wolpert, H. (2021) · Diabetes Technology & Therapeutics
Diabetes Management and ResearchDiabetes Treatment and Management
Cited by 21
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free